-Craig C Earle Researcher Activity Profile

Research Author Detailed Information 

Craig C Earle Publication Rate By Year

Craig C Earle has published 2 paper(s) in 2006, 7 paper(s) in 2007, 6 paper(s) in 2008, for a total of 15 research publications in total.

Craig C Cc Earle Author Information

LAST NAME: earle

FIRST NAME: Craig C

INITIALS: cc

AFFILIATION:

Papers

Craig C Earle's Publication Record

1. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Year Published: 2006
Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, MA 02114, USA. azhu@partners.org
2. Lower use of hospice by cancer patients who live in minority versus white areas. Year Published: 2007
Division of General Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120-1613, USA. jhaas@partners.org
3. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. jmeyerhardt@partners.org
4. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Year Published: 2007
Dana-Farber Cancer Institute, Boston, MA 02115, USA. jmeyerhardt@partners.org
5. Use of palliative radiotherapy among patients with metastatic non-small-cell lung cancer. Year Published: 2007
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109-0010, USA. hayman@umich.edu
6. Use of palliative radiotherapy among patients with metastatic non-small-cell lung cancer. Year Published: 2007
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109-0010, USA. hayman@umich.edu
7. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. jmeyerhardt@partners.org
8. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). Year Published: 2006
Massachusetts General Hospital Cancer Center and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA. lamont@hcp.med.harvard.edu
9. Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder Cancer. Year Published: 2008
Dana-Farber Cancer Institute, Boston, MA, 02115, USA, jmeyerhardt@partners.org.
10. Cancer survivorship research and guidelines: maybe the cart should be beside the horse. Year Published: 2007
11. Trends in Follow-up and Preventive Care for Colorectal Cancer Survivors. Year Published: 2008
Division of General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA, csnyder@jhsph.edu.
12. Trends in follow-up and preventive care for colorectal cancer survivors. Year Published: 2008
Division of General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. csnyder@jhsph.edu
13. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Year Published: 2008
Dana-Farber Cancer Institute, Boston, MA 02115, USA. jmeyerhardt@partners.org
14. Ten-Year Survival and Cost Following Breast Cancer Recurrence: Estimates from SEER-Medicare Data. Year Published: 2008
i3 Innovus, Medford, MA, USA.
15. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Year Published: 2008
i3 Innovus, Medford, MA, USA.